tirzepatide cardiovascular outcomes trial 2024 American Heart Association Scientific Sessions has started off with a bang! Results are in for the SUMMIT study: Treatment with (Mounjaro/ Zepbound) was associated with 38% ⬇️ in combined risk Bridging the gap between GLP1-receptor

(Cost, availability, insurance?) How has Mounjaro been working for you

Therefore, therapeutic principles acting via different receptors and postreceptor pathways seem attractive in view of potentially additive or synergistic effects

The Dual Agonist Breakthrough: Why Two Is Better Than One Tirzepatide, the first dual GLP-1/GIP agonist to reach market, demonstrated that activating both receptors produces superior results to activating GLP-1 alone

The peptide economy is booming

The longer the gap in treatment, the bigger the jump in risk up to a 22% increase for heart attack, stroke and death after two years off GLP-1s, largely erasing the cardiovascular benefits gained during treatment

Oral Tirzepatide questions Things people ask before they sign up